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Abstract 
Background: Malaria is a leading cause of paediatric morbidity and mortality in Uganda. More than half of febrile 
children in rural areas initially seek care at private clinics and drug shops. These shops are generally unregulated and 
the quality of clinical care is variable, with the potential for misdiagnosis and the development of drug resistance. 
There is thus an urgent need to identify rural drug shops and coordinate their malaria treatment efforts with those 
of the public sector. The objective of the study was to identify all drug shops in the Bugoye sub-county of Western 
Uganda and assess their anti-malarial dispensing practices.
Methods: This study is a cross-sectional survey of drug shops in a rural sub-county of Western Uganda. In the first 
phase, shop locations, licensing and shopkeeper’s qualifications, and supply and pricing of anti-malarials were char-
acterized. In the second phase, the proportion of anti-malarials dispensed by private drug shops was compared to 
public health facilities.
Results: A total of 48 drug shops were identified. Only one drug shop (1 of 48, 2%) was licensed with the sub-coun-
ty’s records office. The drug shops stocked a variety of anti-malarials, including first-line therapies and less effective 
agents (e.g., sulfadoxine/pyrimethamine). Almost all drug shops (45 of 48, 94%) provided parenteral anti-malarials. Of 
the 3900 individuals who received anti-malarials during the study, 2080 (53.3%) purchased anti-malarials through the 
private sector compared to 1820 (46.7%) who obtained anti-malarials through the public sector. Drug shops were the 
primary source of parenteral anti-malarials. Inadequate dosing of anti-malarials was more common in drug shops.
Conclusions: Drug shops are major sources of parenteral anti-malarials, which should be reserved for cases of severe 
malaria. Strengthening malaria case management and incorporating drug shops in future interventions is necessary 
to optimize malaria control efforts in the sub-county, and in similarly endemic regions.
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Background
Approximately 30–50% of outpatient visits to public 
healthcare facilities in Uganda are related to malaria, 
which remains a leading cause of paediatric morbidity 
and mortality [1, 2]. However, the private sector is also 
an important source of anti-malarials in rural Uganda, 
where geographic factors such as distance to health 
centres and weak transportation networks can limit 
access to medical care [2–6]. More than half of febrile 
children in rural areas initially seek care at private drug 
shops, which are often unregistered, unregulated, and 
operated by individuals with limited formal clinical 
training [7–13]. A census of drug shops in rural Uganda 
found that 77% were unlicensed [8] and a national sur-
vey that tracked anti-malarial dispensation in Uganda’s 
private sector found that 20.0% of drug shops sold 
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parenteral anti-malarials, a practice that is contrary to 
the policies of Uganda’s Ministry of Health [14].
Drug shops have also been found to market expired 
and/or ineffective anti-malarials despite the availabil-
ity of efficacious first-line therapies, a practice that may 
result in adverse clinical outcomes [15–18]. One study 
found that licensed rural drug shops provided appro-
priate malaria treatments to only 10% of febrile chil-
dren [7], and another study demonstrated that initially 
seeking care at a drug shop was a significant risk factor 
for severe malaria in Ugandan children [19]. These fac-
tors contribute to the highly variable quality of malaria 
case management in drug shops [7, 17, 19–22].
Drug shops do have several advantages compared 
to public facilities, especially in a rural context. They 
are generally more accessible due to their proximity 
to village population centres, shorter waiting times, 
and more flexible hours of operation. They are also 
less prone to drug stock-outs [23–27]. When provided 
with training in basic case management practices, drug 
shops increased patient access to appropriate care [10, 
28, 29]. Thus, there is an urgent need to identify rural 
drug shops, evaluate current practices, and coordinate 
malaria treatment efforts with national guidelines and 
priorities.
This study was a cross-sectional survey examining the 
characteristics of drug shops in Bugoye sub-county, a 
rural area of highland western Uganda whose private sec-
tor has never been assessed. The objective of the study 
was to identify all drug shops in the sub-county and 
assess their anti-malarial dispensing practices in compar-
ison to neighboring public health facilities.
Methods
Study setting
The study was conducted in Bugoye sub-county, Kasese 
District, Western Uganda (Fig.  1). The highland terrain, 
with elevations ranging from 1000 to 1800 m, is home to 
approximately 35,000 residents [30, 31]. Bugoye’s climate 
allows for year-round malaria transmission interspersed 
with semi-annual transmission peaks after the rainy sea-
sons [30]. Recent surveys suggest that malaria transmis-
sion in the region is declining, evidenced by a parasite 
prevalence of 48.4% in 2009 compared to 17.6% in 2014 
[2, 32]. Bugoye sub-county’s health system is divided into 
public and private health facilities.
Public health facilities
The sub-county’s primary public health facility is the 
Bugoye Level III health centre (BHC), which houses an 
inpatient ward where parenteral medications are admin-
istered, an outpatient ward where oral medications are 
dispensed, and a laboratory that conducts point-of-care 
diagnostics including malaria rapid diagnostic tests 
(RDTs) and light microscopy. There are Level II Health 
Centres in each of the six parishes that offer basic outpa-
tient services. There are two community health workers 
termed village health teams (VHTs) in each of the sub-
county’s 36 villages that are trained in integrated com-
munity case management (iCCM), perform RDTs, and 
dispense oral medications to children < 5  years of age 
suffering from uncomplicated pneumonia, diarrhoea, 
and malaria [33]. There is one public–private Level III 
Health Centre operated jointly by the Ugandan Minis-
try of Health and the Rwenzori Mountaineering Services 
(RMS), which houses a public outpatient ward and a 
Fig. 1 Map depicting the locations of public sector health centres and private sector drug shops in Bugoye sub-county (a), with number of 
patients receiving oral anti-malarials during the study period (b), and number of patients receiving parenteral anti-malarials during the study period 
(c)
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private inpatient ward that provide services comparable 
to BHC. Remote villages were defined as those at least 
3 km from BHC.
Private health facilities
To our knowledge, drug shops (i.e., privately owned small 
businesses that sell pharmaceutical products) comprise 
the entirety of the sub-county’s private health facilities.
Study design
This study was a two-phase, cross-sectional survey of 
drug shops in Bugoye sub-county. In the first phase, shop 
locations, self-reported licensing status and shopkeeper’s 
qualifications, and supply and pricing of anti-malarials 
were recorded. In the second phase, the number of anti-
malarials dispensed by private drug shops was compared 
to public health facilities.
Phase 1: initial survey of drug shops
The locations of shops in the sub-county were identified 
with the assistance of local leaders and VHTs. Study staff 
visited all villages at least twice to ensure that no shops 
were missed. At the initial visit, the following information 
was collected on a questionnaire (Additional file  1): the 
village and shop names, GIS coordinates, self-reported 
licensing status, and shopkeeper’s credentials. The fol-
lowing information was recorded for each anti-malarial 
available at a shop: the drug’s trade name, manufacturer’s 
country of origin, formulation and route of administra-
tion, price for an adult and paediatric course (in Ugandan 
shillings), expiration date, and the shop’s current drug 
supply. Study staff also determined the availability and 
cost of malaria RDTs and asked about the shop’s primary 
resupply source. The names of shops that claimed to be 
licensed were compared to a list of licensed drug shops 
maintained by BHC.
Phase 2: tracking anti‑malarial dispensation in drug shops 
and health centres
After completing the initial visit questionnaire, a form 
was provided to each shopkeeper (Additional file  2) 
along with instructions to record anti-malarial sales for 
1  month beginning on 1 August 2017. For every anti-
malarial sold, shopkeepers recorded the following infor-
mation: date of sale, the purchaser’s gender, age, and 
village of residence, the drug name, units dispensed 
(recorded in tablets/bottles/ampules), and the remaining 
stock. Shopkeepers were instructed to return the ques-
tionnaire to BHC after 31 August 2017.
Over the same period, the following information 
on anti-malarial dispensation was extracted from the 
clinical registers of all public health facilities in the sub-
county: date of encounter, patient’s gender, age, village of 
residence, and type and dose of anti-malarial dispensed. 
Records of children < 5  years of age seen by VHTs con-
ducting integrated management of childhood illness 
(IMCI) were collated separately by BHC staff and shared 
with study staff. Anti-malarial tracking forms were not 
provided to public facilities as records were abstracted 
from existing registers.
Anti‑malarial drug courses
The definition of a course of anti-malarials was based 
on WHO guidelines [34]. For example, a course of oral 
artemether/lumefantrine (AL) for an adult > 35  kg con-
sists of 24 tablets (each containing 20  mg artemether 
and 120 mg lumefantrine), with 4 tablets as a single ini-
tial dose, followed by 4 tablets after 8  h, then 4 tablets 
twice a day (AM and PM) for the following 2 days. For an 
adult > 35 kg, a course of parenteral artesunate consists of 
six 60 mg ampules reconstituted in 5% sodium bicarbo-
nate and diluted in 5% (w/v) glucose. A loading dose of 
2 mg/kg is followed by 1 mg/kg after 4 and 24 h; subse-
quently, a dose of 1 mg/kg is given daily until the patient 
can tolerate oral therapy [34].
Statistical analysis
Data were entered into Microsoft Excel, version 15.33 
(Microsoft, Redmond, WA) and analyzed with Stata, ver-
sion 15.1 (Stata Corp., College Station, TX). A map of all 
health facilities was created using ArcGIS, version 10.4.1 
(ESRI, Redlands, CA). The level of owner credentialing 
and self-reported licensing status with the sub-county’s 
records office were summarized, along with the availabil-
ity, formulation, manufacturing origin, and median cost 
of each anti-malarial.
We employed common statistical tests to (1) compare 
patient populations receiving anti-malarials between the 
public and private sector, (2) explore the accuracy of AL 
dosing between the public and private sector, and (3) 
assess for significant differences in the rate of parenteral 
anti-malarial administration across the private sector. 
The demographic characteristics of patients presenting 
to private versus public health facilities were compared 
using Wilcoxon Rank Sum test for continuous variables 
(i.e., age) and Pearson’s Chi squared test for categorical 
variables.
The frequency of inadequate AL dose administration 
was explored in two groups: adults (defined as individu-
als ≥ 21 years of age with a weight assumed to be > 35 kg) 
and children (≤ 5 years of age with a weight assumed to 
be < 15  kg). AL was selected as a proxy for inadequate 
dosing because it is both the first-line therapy for uncom-
plicated malaria and the most commonly prescribed 
anti-malarial in the sub-county. Inadequate dosing was 
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defined as the dispensation of < 6 AL tablets for children 
≤ 5 years of age and < 24 tablets for adults ≥ 21 years of 
age. The proportion of inadequate dosing was compared 
between private and public facilities using Pearson’s Chi 
squared test.
Differences in the relative odds of parenteral anti-
malarial administration across drug shops were examined 
using Poisson regression models. The outcome of interest 
was the route of administration (i.e., parenteral vs. oral) 
and the primary explanatory variable was individual drug 
shops, with BHC serving as the reference. Models were 
adjusted for age and reported as odds ratios (OR). For all 
statistical analyses, a resulting p-value of ≤ 0.05 was con-
sidered significant.
Results
Phase 1: initial survey of drug shops
Licensing and shopkeeper’s qualifications
A total of 48 drug shops were identified (Fig. 1a) and all 
shopkeepers consented to participate in the study. Only 
one shop (1 of 48, 2.1%) was licensed with the sub-coun-
ty’s records office. Some shops (16 of 48, 33%) had more 
than one shopkeeper; most (48 of 67, 72%) identified 
themselves as nursing assistants, which in Uganda quali-
fies one to dispense medications under supervision.
Supply and pricing of anti‑malarials
The drug shops stocked a variety of anti-malarials 
(Table 1). Nearly all shops (47 of 48, 98.0%) stocked AL 
at a median cost of $1.11 (IQR 1.11–1.28) for an adult 
course of 24 tablets. Quinine was available in tablet (43 of 
48, 90%), syrup (48 of 48, 100%), and parenteral forms (45 
of 48, 94%). Older agents like sulfadoxine/pyrimethamine 
(SP) that are no longer considered effective for the treat-
ment of uncomplicated malaria [35] were also available in 
drug shop (42 of 48, 88.0%). In general, parenteral anti-
malarials were more expensive, with an adult course of 
6 ampules of parenteral artesunate (median cost $13.33, 
IQR 13.33–13.33) being the most expensive treatment. 
None of the anti-malarials examined on the initial visit 
were expired. All shops reported restocking supplies 
from pharmacies in Kasese Town, approximately 20 km 
to the south. All shops offered malaria RDTs for a median 
cost of $0.56 (IQR $0.56–$0.83).
Phase 2: tracking anti‑malarial dispensation in drug shops 
and health centres
Completed tracking forms were received from all 48 drug 
shops. Of the 3900 individuals who received anti-malar-
ials from private and public facilities during the study 
period, 2080 (53.3%) received anti-malarials through 
private facilities compared to 1820 (46.7%) who received 
anti-malarials through public facilities. Nearly all care 
on the weekends (503 of 515, 97.7%, Table  2) was pro-
vided by drug shops. Health centres were the primary 
source of AL, while drug shops dispensed more doses of 
every other type of anti-malarial, including less effica-
cious therapies such as SP and chloroquine (Table 3). All 
patients who received anti-malarials from a health centre 
had a positive RDT.
Geographic characteristics of drug shops
Most shops distributing anti-malarials were located 
within 1  km of a health centre (Fig.  1b, c). Individuals 
from villages with a health centre were equally as likely 
to obtain anti-malarials from a drug shop as those from 
Table 1 Anti-malarial drugs available in drug shops in Bugoye sub-county
a Number (and definition) of adult courses available in all drug shops
b Cost in US dollars of a single adult course of specified anti-malarial
Drug name Formulation Adult  coursesa Costb (median, IQR) Drug shops (n, %)
Oral formulations
 Amodiaquine Tablet 9.5 (6 tablets) 2.08 (1.46–2.78) 6/48 (13)
 Artemether Tablet 0 (12 tablets) 1.81 (1.32–2.78) 2/48 (4)
 Artemether/lumefantrine Tablet 316.8 (24 tablets) 1.11 (1.11–1.28) 47/48 (98)
 Chloroquine Tablet 6.1 (10 tablets) 1.11 (0.83–1.11) 4/48 (8)
 Dihydroartemisinin/piperaquine Tablet 15.6 (9 tablets) 4.17 (4.17–6.94) 7/48 (15)
 Quinine Syrup 99 (1 bottle) 1.11 (1.11–1.39) 48/48 (100)
 Quinine Tablet 31.7 (30 tablets) 2.50 (2.08–2.50) 43/48 (90)
 Sulfadoxine/pyrimethamine Tablet 243.8 (3 tablets) 0.42 (0.42–0.54) 42/48 (88)
Parenteral formulations
 Artemether Parenteral 6.5 (6 ampules) 4.58 (3.13–8.33) 9/48 (19)
 Artesunate Parenteral 13.8 (6 ampules) 13.33 (13.33–13.33) 22/48 (46)
 Quinine Parenteral 60.7 (3 ampules) 8.06 (5.56–8.33) 45/48 (94)
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villages without a health centre (AOR 1.00, 95% CI 0.88–
1.15, p = 0.97, Table  2). Conversely, individuals from 
remote villages furthest from BHC were more likely to 
obtain anti-malarials from drug shops (AOR 1.28, 95% CI 
1.09–1.51, p = 0.002, Table 2).
Patient characteristics
Individuals receiving all types of anti-malarials from drug 
shops were slightly older than those that received all 
types of anti-malarials through health centres (median 
age 19 vs. 16 years, p = 0.004, Table 2). One half of indi-
viduals (165 of 329, 50.2%) treated with SP in drug shops 
were male, suggesting that intermittent treatment of 
malaria in pregnancy (IPTp) was not the rationale for 
selecting SP.
Parenteral anti‑malarial dispensation
59 of 299 (19.7%) individuals treated for malaria at BHC 
received parenteral anti-malarials, consisting of either 
artesunate (47 of 59, 79.7%) or quinine (12 of 59, 20.3%). 
An additional 36 of 45 (80.0%) patients treated in the pri-
vate inpatient ward of the RMS health centre received 
parenteral anti-malarials. All patients who received a 
course of parenteral anti-malarials at a Level III health 
centre also received a course of oral anti-malarials. 
Together, these two Level III facilities accounted for only 
95 of the 448 (21.2%) individuals that received parenteral 
anti-malarials over the study period (Fig. 2).
In contrast, drug shops accounted for 353 of the 448 
(78.8%) individuals that received parenteral anti-malar-
ials over the study period (Fig.  2). The administration 
of parenteral anti-malarials in drug shops was common 
practice (Fig. 1c), with most shops (40 of 48, 83.4%) dis-
pensing parenteral anti-malarials to at least one person 
over the study period. Quinine was the most frequently 
sold parenteral anti-malarial (251 of 353, 71.7%), followed 
by artesunate (71 of 353, 20.1%) and artemether (31 of 
353, 8.9%). None of the patients who purchased paren-
teral anti-malarials from a shop purchased a concomitant 
course of oral anti-malarials. Five drug shops (5 of 48, 
10.4%) accounted for 37.7% of individuals treated with 
parenteral anti-malarials in the private sector.
Table 2 Demographic characteristics of  patients in  the   
public and private sectors
a Excludes 289 (7.4%) patients < 5 years of age treated by VHTs
b Includes the 45 patients seen at the private RMS Level III Health Centre
c Defined as villages at least 3 km from the Bugoye Level III Health Centre
d Probability obtained by comparison of medians using Mann–Whitney two 
sample test
Public health 
 centresa
Drug  shopsb p‑value
Patients (n, %) 1531 (39.3) 2080 (53.3) –
Female (n, %) 877 (57.3) 1063 (53.3) 0.018
Age (median, IQR) 16 (9–27) 19 (9–30) 0.004d
Age category (n, %) (years)
 < 5 166 (10.9) 306 (14.8) < 0.001
 5–12 366 (24.1) 320 (15.5)
 > 12 989 (65.0) 1443 (69.7)
 Villages with health 
centre
685 (44.8) 923 (44.7) 0.97
 Remote  villagesc 295 (19.3) 486 (23.6) 0.002
 Weekend 12 (0.8) 503 (25.6) < 0.001
Table 3 Number of patients treated in the public sector versus the private sector
a All seven individuals were children < 5 years of age treated by VHTs
b The aggregate number of patients treated is less than the numbers reported in the table because some patients received more than one type of anti-malarial
Formulation Anti‑malarial Patients  treatedb (n, %)
Public sector
1820 (46.7)
Private sector
2080 (53.3)
Tablets Amodiaquine 0 0
Artemether 0 5 (0.2)
Artemether/lumefantrine 1715 (94.2) 1029 (49.5)
Chloroquine 0 3 (0.1)
Dihydroartemisinin/piperaquine 0 19 (0.9)
Quinine 2 (0.1) 169 (8.1)
Sulfadoxine/pyrimethamine 96 (5.3) 341 (16.4)
Parenteral Artemether 0 31 (1.5)
Artesunate 47 (2.6) 73 (3.5)
Quinine 12 (0.7) 285 (13.7)
Syrup Quinine 0 164 (7.9)
Rectal Artesunate 7 (0.4)a 0
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In the regression analysis, receiving care at drug shops 
was associated with significantly higher odds of paren-
teral anti-malarial use (AOR 5.05, 95% CI 3.80–6.72, 
p < 0.001) compared to BHC. At eight shops, the odds of 
parenteral anti-malarial sales were significantly higher 
(p < 0.05) or trended higher (p < 0.1) than that observed at 
BHC. Together, these eight shops accounted for 31.3% of 
individuals treated with parenteral anti-malarials in both 
the public and private sectors. Of these eight shops, four 
were in trading centres adjacent to BHC and two were 
near RMS.
Individuals receiving parenteral treatment in drug 
shops were on average 7.8 years older than those receiv-
ing treatment at BHC (22.7 vs. 15.0 years, p < 0.001). Sim-
ilarly, children < 5  years of age presented less frequently 
to drug shops compared to BHC to receive parenteral 
therapy (30.8% vs. 69.2%, p < 0.001). There were no sig-
nificant differences by gender.
Inadequate AL dosing in drug shops
Inadequate AL dosing among children was not observed 
in health centres (0 of 137 cases, 0.0%). However, inad-
equate AL dosing was relatively frequent in drug shops 
(11 of 94 cases, 11.7%). Inadequate AL dosing among 
adults was also more common at drug shops (65 of 410 
cases, 15.9%) compared to health centres (8 of 526 cases, 
1.5%, p < 0.001). There was no significant difference in 
the age of adults between private and public facilities 
(p = 0.80) that might explain the difference in AL dosing. 
Furthermore, adult women (who may weigh less than the 
35-kg threshold for a 24 tablet AL course) comprised a 
higher, albeit non-significant, proportion of attendees 
at public compared to private health facilities (57.2 vs. 
Fig. 2 Number of individuals receiving parenteral anti-malarial therapy at the Bugoye Level III Health Centre compared to private sector drug shops 
during the study period (1–31 August 2017)
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52.4, p = 0.14), which makes this unlikely to explain the 
observed differences.
Discussion
This study demonstrates that private sector drug shops 
are not only significant distributors of anti-malarials in 
a rural area of western Uganda, but also a major source 
of parenteral anti-malarials. Although Uganda’s National 
Drug Authority does not authorize drug shops to dis-
pense parenteral medications, a 2015 national survey 
found that 20.0% of drug shops sold parenteral quinine 
and 10.9% sold parenteral artemether. Ultimately, 8.7% 
of patients received non-artemisinin therapies (i.e., par-
enteral/tablet/syrup quinine, SP tablets, or chloroquine 
tablets) and 3.9% of patients received an artemisinin 
monotherapy (i.e., parenteral artemether) during the 
national survey’s data collection period [14]. The pre-
sent study found that both the percentage of drug shops 
selling parenteral anti-malarials and the percentage of 
patients receiving parenteral anti-malarials were greater 
than previously reported. Even shops located near Level 
III facilities had high rates of parenteral anti-malarial 
sales, indicating a strong preference for seeking care in 
the private sector.
Several factors may account for increased utilization 
of drug shops in Bugoye sub-county. Long wait times 
at public health facilities, coupled with the convenience 
of seeking care in drug shops, likely led to increased 
acquisition of parenteral anti-malarials through the pri-
vate sector. Patients may believe that parenteral anti-
malarials are more efficacious than oral formulations, a 
perception that has been shown in other countries [36]. 
Furthermore, this study found that older patients were 
not only more likely to seek care in drug shops, but also 
more likely to purchase parenteral anti-malarials without 
an accompanying course of oral anti-malarials. On the 
other hand, paediatric patients were less likely to present 
to a shop and receive parenteral therapy. This could be 
because parents, concerned that their child might be suf-
fering from severe malaria, seek formal treatment from a 
public facility staffed by more qualified personnel.
These results have important public health implica-
tions. In terms of patient safety, the dispensation of par-
enteral anti-malarials in drug shops raises concerns about 
safety practices, management of adverse drug effects, and 
possible dispensation of counterfeit drugs. In particular, 
parenteral quinine can have dangerous adverse effects if 
improperly administered. In terms of anti-malarial stew-
ardship, all drug shops dispensed a course of parenteral 
anti-malarials without a concomitant course of oral anti-
malarials, a practice that can lead to the development of 
drug resistance. Additionally, previous studies have found 
that initially seeking care at drug shops was a significant 
risk factor for severe malaria in Ugandan children, likely 
due to their provision of sub-optimal treatments and 
resultant disease progression [19, 37].
Several approaches could be taken to address these 
complex issues. A ban on parenteral anti-malarial dis-
pensation in drug shops could be enforced, but may push 
sales further underground, where they will be even more 
difficult to regulate. Another option is a harm reduction 
approach, which could include more training for shop-
keepers and more rigorous enforcement of licensing and 
RDT usage. The results of our analysis indicate that tar-
geting a few high-volume drug shops could have an expo-
nential impact on malaria case control.
This study has several methodological strengths, 
including its rigorous field practices identifying drug 
shops and its high response rate. This study also has 
some limitations. First, the data was drawn from clinic 
records in public facilities and from self-reported records 
in drug shops whose accuracy were not assessed. How-
ever, the rate of completeness was high and there is no 
reason to believe there were systemic issues in reporting. 
Second, study staff did not interview customers and thus 
can only speculate on the motivations driving their care-
seeking behaviors. These behaviors can be examined in 
future qualitative studies. Third, this study did not track 
the degree of overlapping patient utilization of the pub-
lic and private sector. Finally, RDT utilization in drug 
shops was not assessed and it is unknown whether the 
2080 individuals that received anti-malarials through the 
private sector actually had clinical malaria. Regardless, 
these limitations do not diminish the striking finding that 
the majority of parenteral anti-malarials were dispensed 
through private drug shops.
Conclusions
Private sector drug shops in Bugoye sub-county dis-
tributed more than half of all anti-malarials during the 
study period and were the primary source of paren-
teral anti-malarials. There were several risks associated 
with seeking care in drug shops, including higher rates 
of inadequate anti-malarial dosing. Further studies are 
needed to assess the potential risks and benefits of incor-
porating drug shops as stakeholders in malaria case man-
agement in Uganda.
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